爆诺华53亿美元收购干眼病药物lif

近期诺华刚剥离爱尔康，武田刚亿美元收购Shire，都面临战略调整，诺华此次加强眼科领域的核心地位，武田聚焦更核心的胃肠道、罕见病、肿瘤、神经系统等疾病，将剥离亿美元左右非核心资产。lifitegrast是夏尔的上市眼科药，很明显武田收购后需要偿还债务。

53亿美元的分子

Xiidra(lifitegrastophthalmicsolution)5%fitsstrategicallywithinindustry-leadingUSD4.6billionNovartisophthalmicpharmaceuticalportfolio,layinggroundworkforfront-of-the-eyepipelineproductscurrentlyindevelopment

Xiidraisthefirstandonlyprescriptiontreatmentapprovedforbothsignsandsymptomsofdryeyediseasewithamechanismofactionthattargetsinflammation

XiidraachievedUSD0.4billionofrevenueinandiswellpositionedforblockbusterpotential;closingexpectedinsecondhalfof,subjecttosatisfactionofcustomaryclosingconditions,includingregulatoryapprovals

DealtermsincludeaUSD3.4billionupfrontpaymentwithpotentialmilestonepaymentsofuptoUSD1.9billion

Thenews

转载请注明：http://www.masshuanghu.com/jbby/5624.html